Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Friday, January 12, 2018 9:46:25 AM
On January 9, 2018, Crystal Equity Research published an initial report on PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (http://nnw.fm/aO8gG), a biomedical company with a focus on preventative health sciences. Among other highlights, the report noted the company’s recapitalization efforts to fund its development program, as well as the strategic mergers and distribution agreements to address additional markets, including the sports medicine market. The company’s initial product, CELLB9, is an innovative therapy based on blue scorpion venom. The sales from CELLB9 represent the company’s current revenue stream, which helps to balance out research and developmental spending.
To view the full press release, visit http://nnw.fm/3qvyI
About PreveCeutical
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information about the company, visit www.PreveCeutical.com
Recent PRVCF News
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM